Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
1,000 34 39 34 39 B-lower_bound
/ 39 40 39 40 I-lower_bound
uL 40 42 40 42 I-lower_bound

Active 0 6 43 49 B-chronic_disease
infection 7 16 50 59 I-chronic_disease
or 17 19 60 62 O
other 20 25 63 68 O
medical 26 33 69 76 O
condition 34 43 77 86 O
which 44 49 87 92 O
would 50 55 93 98 O
preclude 56 64 99 107 O
treatment 65 74 108 117 B-treatment
in 75 77 118 120 O
the 78 81 121 124 O
opinion 82 89 125 132 O
of 90 92 133 135 O
the 93 96 136 139 O
principal 97 106 140 149 O
investigator 107 119 150 162 O
; 119 120 162 163 O
this 121 125 164 168 O
would 126 131 169 174 O
include 132 139 175 182 O
a 140 141 183 184 O
corrected 142 151 185 194 O
diffusing 152 161 195 204 B-clinical_variable
capacity 162 170 205 213 I-clinical_variable
of 171 173 214 216 I-clinical_variable
the 174 177 217 220 I-clinical_variable
lungs 178 183 221 226 I-clinical_variable
for 184 187 227 230 I-clinical_variable
carbon 188 194 231 237 I-clinical_variable
monoxide 195 203 238 246 I-clinical_variable
( 204 205 247 248 I-clinical_variable
DLCO 205 209 248 252 I-clinical_variable
) 209 210 252 253 I-clinical_variable
of 211 213 254 256 O
< 214 215 257 258 O
60 216 218 259 261 B-upper_bound
% 218 219 261 262 I-upper_bound
predicted 220 229 263 272 O
or 230 232 273 275 O
symptomatic 233 244 276 287 O
interstitial 245 257 288 300 B-chronic_disease
lung 258 262 301 305 I-chronic_disease
disease 263 270 306 313 I-chronic_disease

Aspartate 0 9 314 323 B-clinical_variable
aminotransferase 10 26 324 340 I-clinical_variable
( 27 28 341 342 I-clinical_variable
AST 28 31 342 345 I-clinical_variable
) 31 32 345 346 I-clinical_variable
and 33 36 347 350 O
alanine 37 44 351 358 B-clinical_variable
aminotransferase 45 61 359 375 I-clinical_variable
( 62 63 376 377 I-clinical_variable
ALT 63 66 377 380 I-clinical_variable
) 66 67 380 381 I-clinical_variable
< 68 69 382 383 O
2.5 70 73 384 387 B-upper_bound
x 74 75 388 389 I-upper_bound
ULN 76 79 390 393 I-upper_bound

Bilirubin 0 9 394 403 B-clinical_variable
< 10 11 404 405 O
1.5 12 15 406 409 B-upper_bound
x 16 17 410 411 I-upper_bound
upper 18 23 412 417 I-upper_bound
limit 24 29 418 423 I-upper_bound
of 30 32 424 426 I-upper_bound
normal 33 39 427 433 I-upper_bound
( 40 41 434 435 I-upper_bound
ULN 41 44 435 438 I-upper_bound
) 44 45 438 439 I-upper_bound

Documented 0 10 440 450 O
expression 11 21 451 461 O
of 22 24 462 464 O
CD30 25 29 465 469 O
on 30 32 470 472 O
tumor 33 38 473 478 B-cancer
cells 39 44 479 484 I-cancer

Eastern 0 7 485 492 B-clinical_variable
Cooperative 8 19 493 504 I-clinical_variable
Oncology 20 28 505 513 I-clinical_variable
Group 29 34 514 519 I-clinical_variable
( 35 36 520 521 I-clinical_variable
ECOG 36 40 521 525 I-clinical_variable
) 40 41 525 526 I-clinical_variable
performance 42 53 527 538 I-clinical_variable
status 54 60 539 545 I-clinical_variable
> 61 62 546 547 O
2 63 64 548 549 B-lower_bound

Expected 0 8 550 558 O
survival 9 17 559 567 O
if 18 20 568 570 O
untreated 21 30 571 580 O
of 31 33 581 583 O
> 34 35 584 585 O
90 36 38 586 588 B-lower_bound
days 39 43 589 593 I-lower_bound

Intolerance 0 11 594 605 O
to 12 14 606 608 O
brentuximab 15 26 609 620 B-treatment
vedotin 27 34 621 628 I-treatment

Known 0 5 629 634 O
human 6 11 635 640 B-chronic_disease
immunodeficiency 12 28 641 657 I-chronic_disease
virus 29 34 658 663 I-chronic_disease
( 35 36 664 665 I-chronic_disease
HIV 36 39 665 668 I-chronic_disease
) 39 40 668 669 I-chronic_disease
or 41 43 670 672 O
hepatitis 44 53 673 682 B-chronic_disease
B 54 55 683 684 I-chronic_disease
positivity 56 66 685 695 O
or 67 69 696 698 O
prior 70 75 699 704 O
progressive 76 87 705 716 B-chronic_disease
multifocal 88 98 717 727 I-chronic_disease
leukoencephalopathy 99 118 728 747 I-chronic_disease
( 119 120 748 749 I-chronic_disease
PML 120 123 749 752 I-chronic_disease
) 123 124 752 753 I-chronic_disease

Measurable 0 10 754 764 O
disease 11 18 765 772 O
by 19 21 773 775 O
computed 22 30 776 784 B-treatment
tomography 31 41 785 795 I-treatment
( 42 43 796 797 I-treatment
CT 43 45 797 799 I-treatment
) 45 46 799 800 I-treatment
or 47 49 801 803 O
similar 50 57 804 811 O
( 58 59 812 813 O
e.g. 59 63 813 817 O
magnetic 64 72 818 826 B-clinical_variable
resonance 73 82 827 836 I-clinical_variable
imaging 83 90 837 844 I-clinical_variable
[ 91 92 845 846 I-clinical_variable
MRI 92 95 846 849 I-clinical_variable
] 95 96 849 850 I-clinical_variable
) 96 97 850 851 I-clinical_variable
criteria 98 106 852 860 I-clinical_variable
( 107 108 861 862 O
> 108 109 862 863 O
1.5 110 113 864 867 B-lower_bound
cm 114 116 868 870 I-lower_bound
) 116 117 870 871 O

Patients 0 8 872 880 O
must 9 13 881 885 O
be 14 16 886 888 O
anticipated 17 28 889 900 O
to 29 31 901 903 O
complete 32 40 904 912 O
at 41 43 913 915 O
least 44 49 916 921 O
2 50 51 922 923 B-lower_bound
cycles 52 58 924 930 O
of 59 61 931 933 O
chemotherapy 62 74 934 946 B-treatment
on 75 77 947 949 O
study 78 83 950 955 O

Platelets 0 9 956 965 B-clinical_variable
> 10 11 966 967 O
50,000 12 18 968 974 B-lower_bound
/ 18 19 974 975 I-lower_bound
uL 19 21 975 977 I-lower_bound

Pregnancy 0 9 978 987 B-pregnancy

Prior 0 5 988 993 B-treatment
transplant 6 16 994 1004 I-treatment
within 17 23 1005 1011 O
100 24 27 1012 1015 B-upper_bound
days 28 32 1016 1020 I-upper_bound

Radioimmunotherapy 0 18 1021 1039 B-treatment
within 19 25 1040 1046 O
12 26 28 1047 1049 B-upper_bound
weeks 29 34 1050 1055 I-upper_bound

Relapsed 0 8 1056 1064 B-cancer
or 9 11 1065 1067 I-cancer
refractory 12 22 1068 1078 I-cancer
CD30 23 27 1079 1083 I-cancer
+ 27 28 1083 1084 I-cancer
lymphoma 29 37 1085 1093 I-cancer
that 38 42 1094 1098 O
has 43 46 1099 1102 O
either 47 53 1103 1109 O
achieved 54 62 1110 1118 O
< 63 64 1119 1120 O
PR 65 67 1121 1123 O
to 68 70 1124 1126 O
brentuximab 71 82 1127 1138 B-treatment
vedotin 83 90 1139 1146 I-treatment
( 91 92 1147 1148 O
minimum 92 99 1148 1155 O
of 100 102 1156 1158 O
2 103 104 1159 1160 O
cycles 105 111 1161 1167 O
) 111 112 1167 1168 O
, 112 113 1168 1169 O
progressed 114 124 1170 1180 O
while 125 130 1181 1186 O
receiving 131 140 1187 1196 O
brentuximab 141 152 1197 1208 O
vedotin 153 160 1209 1216 O
, 160 161 1216 1217 O
or 162 164 1218 1220 O
progressed 165 175 1221 1231 O
within 176 182 1232 1238 O
6 183 184 1239 1240 B-upper_bound
months 185 191 1241 1247 I-upper_bound
of 192 194 1248 1250 O
the 195 198 1251 1254 O
last 199 203 1255 1259 O
dose 204 208 1260 1264 O
of 209 211 1265 1267 O
brentuximab 212 223 1268 1279 O
vedotin 224 231 1280 1287 O

Resolution 0 10 1288 1298 O
of 11 13 1299 1301 O
all 14 17 1302 1305 O
non 18 21 1306 1309 B-cancer
- 21 22 1309 1310 I-cancer
hematologic 22 33 1310 1321 I-cancer
brentuximab 34 45 1322 1333 B-treatment
vedotin 46 53 1334 1341 B-treatment
- 53 54 1341 1342 O
related 54 61 1342 1349 O
adverse 62 69 1350 1357 B-clinical_variable
events 70 76 1358 1364 I-clinical_variable
( 77 78 1365 1366 I-clinical_variable
AEs 78 81 1366 1369 I-clinical_variable
) 81 82 1369 1370 I-clinical_variable
to 83 85 1371 1373 O
< 86 87 1374 1375 O
grade 88 93 1376 1381 B-upper_bound
2 94 95 1382 1383 I-upper_bound

Serum 0 5 1384 1389 B-clinical_variable
creatinine 6 16 1390 1400 I-clinical_variable
< 17 18 1401 1402 O
1.5 19 22 1403 1406 B-upper_bound
mg 23 25 1407 1409 I-upper_bound
/ 25 26 1409 1410 I-upper_bound
dL 26 28 1410 1412 I-upper_bound

any 0 3 1413 1416 O
peripheral 4 14 1417 1427 B-clinical_variable
neuropathy 15 25 1428 1438 I-clinical_variable
> 26 27 1439 1440 O
grade 28 33 1441 1446 O
2 34 35 1447 1448 B-lower_bound

creatinine 0 10 1449 1459 B-clinical_variable
clearance 11 20 1460 1469 I-clinical_variable
> 21 22 1470 1471 O
60 23 25 1472 1474 B-lower_bound
mL 26 28 1475 1477 I-lower_bound
/ 28 29 1477 1478 I-lower_bound
min 29 32 1478 1481 I-lower_bound

females 0 7 1482 1489 B-gender
of 8 10 1490 1492 O
childbearing 11 23 1493 1505 O
potential 24 33 1506 1515 O
and 34 37 1516 1519 O
males 38 43 1520 1525 O
who 44 47 1526 1529 O
have 48 52 1530 1534 O
partners 53 61 1535 1543 O
of 62 64 1544 1546 O
childbearing 65 77 1547 1559 O
potential 78 87 1560 1569 O
must 88 92 1570 1574 O
agree 93 98 1575 1580 B-contraception_consent
to 99 101 1581 1583 I-contraception_consent
use 102 105 1584 1587 I-contraception_consent
2 106 107 1588 1589 I-contraception_consent
effective 108 117 1590 1599 I-contraception_consent
contraceptive 118 131 1600 1613 I-contraception_consent
methods 132 139 1614 1621 I-contraception_consent
during 140 146 1622 1628 O
the 147 150 1629 1632 O
study 151 156 1633 1638 O
and 157 160 1639 1642 O
for 161 164 1643 1646 O
6 165 166 1647 1648 B-upper_bound
months 167 173 1649 1655 I-upper_bound
following 174 183 1656 1665 O
the 184 187 1666 1669 O
last 188 192 1670 1674 O
dose 193 197 1675 1679 O
of 198 200 1680 1682 O
brentuximab 201 212 1683 1694 B-treatment
vedotin 213 220 1695 1702 I-treatment
or 221 223 1703 1705 O
8 224 225 1706 1707 B-upper_bound
months 226 232 1708 1714 I-upper_bound
following 233 242 1715 1724 O
the 243 246 1725 1728 O
last 247 251 1729 1733 O
dose 252 256 1734 1738 O
of 257 259 1739 1741 O
nivolumab 260 269 1742 1751 B-treatment
, 269 270 1751 1752 O
whichever 271 280 1753 1762 O
is 281 283 1763 1765 O
later 284 289 1766 1771 O
) 289 290 1771 1772 O

females 0 7 1773 1780 B-gender
of 8 10 1781 1783 O
childbearing 11 23 1784 1796 O
potential 24 33 1797 1806 O
must 34 38 1807 1811 O
have 39 43 1812 1816 O
a 44 45 1817 1818 O
negative 46 54 1819 1827 B-pregnancy
serum 55 60 1828 1833 I-pregnancy
or 61 63 1834 1836 I-pregnancy
urine 64 69 1837 1842 I-pregnancy
beta 70 74 1843 1847 I-pregnancy
human 75 80 1848 1853 I-pregnancy
chorionic 81 90 1854 1863 I-pregnancy
gonadotropin 91 103 1864 1876 I-pregnancy
[ 104 105 1877 1878 I-pregnancy
beta 105 109 1878 1882 I-pregnancy
- 109 110 1882 1883 I-pregnancy
hCG 110 113 1883 1886 I-pregnancy
] 113 114 1886 1887 I-pregnancy
pregnancy 115 124 1888 1897 I-pregnancy
test 125 129 1898 1902 O
result 130 136 1903 1909 O
within 137 143 1910 1916 O
7 144 145 1917 1918 B-upper_bound
days 146 150 1919 1923 I-upper_bound
prior 151 156 1924 1929 I-upper_bound
to 157 159 1930 1932 O
the 160 163 1933 1936 O
first 164 169 1937 1942 O
dose 170 174 1943 1947 O
of 175 177 1948 1950 O
brentuximab 178 189 1951 1962 B-treatment
vedotin 190 197 1963 1970 I-treatment

females 0 7 1971 1978 B-gender
of 8 10 1979 1981 O
non 11 14 1982 1985 O
- 14 15 1985 1986 O
childbearing 15 27 1986 1998 O
potential 28 37 1999 2008 O
are 38 41 2009 2012 O
those 42 47 2013 2018 O
who 48 51 2019 2022 O
are 52 55 2023 2026 O
postmenopausal 56 70 2027 2041 O
greater 71 78 2042 2049 O
than 79 83 2050 2054 O
1 84 85 2055 2056 B-lower_bound
year 86 90 2057 2061 I-lower_bound
or 91 93 2062 2064 O
who 94 97 2065 2068 O
have 98 102 2069 2073 O
had 103 106 2074 2077 O
a 107 108 2078 2079 O
bilateral 109 118 2080 2089 B-treatment
tubal 119 124 2090 2095 I-treatment
ligation 125 133 2096 2104 I-treatment
or 134 136 2105 2107 O
hysterectomy 137 149 2108 2120 B-treatment

females 0 7 2121 2128 B-gender
with 8 12 2129 2133 O
false 13 18 2134 2139 O
positive 19 27 2140 2148 O
results 28 35 2149 2156 O
and 36 39 2157 2160 O
documented 40 50 2161 2171 O
verification 51 63 2172 2184 O
that 64 68 2185 2189 O
the 69 72 2190 2193 O
patient 73 80 2194 2201 O
is 81 83 2202 2204 O
not 84 87 2205 2208 B-pregnancy
pregnant 88 96 2209 2217 I-pregnancy
are 97 100 2218 2221 O
eligible 101 109 2222 2230 O
for 110 113 2231 2234 O
participation 114 127 2235 2248 O

vitiligo 0 8 2249 2257 B-chronic_disease
and 9 12 2258 2261 O
autoimmune 13 23 2262 2272 B-chronic_disease
alopecia 24 32 2273 2281 I-chronic_disease
( 33 34 2282 2283 O
Arm 34 37 2283 2286 O
B 38 39 2287 2288 O
only 40 44 2289 2293 O
) 44 45 2293 2294 O

